Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT)Research in context

Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT)Research in context

Summary: Background: Rovunaptabin neutralises functional autoantibodies targeting G-Protein coupled receptors (GPCR-fAAbs), observed in patients with Post-COVID syndrome. As we hypothesise an improvement of PCS by rovunaptabin, the aim of reCOVer was to investigate safety, tolerability, and clinica...

Full description

Saved in:
Bibliographic Details
Main Authors: Bettina Hohberger, Marion Ganslmayer, Thomas Harrer, Friedrich Kruse, Stefanie Maas, Tobias Borst, Ralph Heimke-Brinck, Andreas Stog, Thomas Knauer, Eva Rühl, Victoria Zeisberg, Adam Skornia, Alexander Bartsch, Armin Ströbel, Monika Wytopil, Caroline Merkel, Sophia Hofmann, Katja G. Schmidt, Petra Lakatos, Julia Schottenhamml, Martin Herrmann, Christian Mardin, Jürgen Rech
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:EClinicalMedicine
Subjects:
Post-COVID syndrome
Long-COVID
Rovunaptabin
PCS subtypes
GPCR
Functional autoantibody
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537025002901
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2589537025002901

Similar Items